{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:31:01Z","timestamp":1793784661906,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbrc.2026.154712","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:14:30Z","timestamp":1791587670000},"page":"154712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["OTUD7B associates with immune infiltration and pharmacogenomic profiles in hepatocellular carcinoma: An integrative multi-omics analysis"],"prefix":"10.1016","volume":"839","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1568-2563","authenticated-orcid":false,"given":"Mehtap","family":"Ulker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1311-2314","authenticated-orcid":false,"given":"Cigdem","family":"Aydin Acar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbrc.2026.154712_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154712_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.bbrc.2026.154712_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.bbrc.2026.154712_bib4","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/ijms26051936","article-title":"Advances in immunotherapy in hepatocellular carcinoma","volume":"26","author":"Bloom","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.bbrc.2026.154712_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154712_bib6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12672-025-02773-z","article-title":"Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions","volume":"16","author":"Sadrinasab","year":"2025","journal-title":"Discov. Oncol."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154712_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11938-021-00346-x","article-title":"Recent progress in systemic therapy for hepatocellular cancer (HCC)","volume":"19","author":"Ghaziani","year":"2021","journal-title":"Curr. Treat. Options Gastroenterol."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154712_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"10126","key":"10.1016\/j.bbrc.2026.154712_bib9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2026.154712_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.021908.132629","article-title":"The liver as a lymphoid organ","volume":"27","author":"Crispe","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154712_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver--from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2026.154712_bib12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbrc.2026.154712_bib13","doi-asserted-by":"crossref","first-page":"101234","DOI":"10.1016\/j.neo.2025.101234","article-title":"PD-L1(+) tumor-associated macrophages induce CD8(+) T cell exhaustion in hepatocellular carcinoma","volume":"69","author":"Nosaka","year":"2025","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.bbrc.2026.154712_bib14","first-page":"1176","article-title":"PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma","volume":"71","author":"Lu","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.bbrc.2026.154712_bib15","article-title":"Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications","volume":"16","author":"Gao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154712_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12967-015-0396-1","article-title":"Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma","volume":"13","author":"Wang","year":"2015","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154712_bib17","article-title":"USP7 \u2013 a crucial regulator of cancer hallmarks","volume":"1878","author":"Saha","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"6","key":"10.1016\/j.bbrc.2026.154712_bib18","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.7150\/thno.103012","article-title":"OTUD7B is a new deubiquitinase targeting p53","volume":"15","author":"Ding","year":"2025","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.bbrc.2026.154712_bib19","article-title":"Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bbrc.2026.154712_bib20","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.3390\/ijms24076495","article-title":"Navigating through the PD-1\/PDL-1 landscape: a systematic review and meta-analysis of clinical outcomes in hepatocellular carcinoma and their influence on immunotherapy and tumor microenvironment","volume":"24","author":"Ailia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bbrc.2026.154712_bib21","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.3390\/ijms25052939","article-title":"Programmed death ligand 1 regulatory crosstalk with ubiquitination and deubiquitination: implications in cancer immunotherapy","volume":"25","author":"Kim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bbrc.2026.154712_bib22","first-page":"1887","article-title":"Advances in tumor microenvironment and immunotherapeutic strategies for hepatocellular carcinoma","volume":"33","author":"Xue","year":"2025","journal-title":"Oncol. Res."},{"issue":"D1","key":"10.1016\/j.bbrc.2026.154712_bib23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analysis for any organism","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2026.154712_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: an update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.bbrc.2026.154712_bib25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"issue":"W1","key":"10.1016\/j.bbrc.2026.154712_bib26","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"10.1016\/j.bbrc.2026.154712_bib27","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"10.1016\/j.bbrc.2026.154712_bib28","first-page":"558","article-title":"GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels","volume":"51","author":"Liu","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2026.154712_bib29","article-title":"The role of m6A RNA methylation in cancer: implication for nature products anti-cancer research","volume":"13","author":"Song","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"Database issue","key":"10.1016\/j.bbrc.2026.154712_bib30","first-page":"D955","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.bbrc.2026.154712_bib31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell"},{"issue":"10360","key":"10.1016\/j.bbrc.2026.154712_bib32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"ESMO Guidelines Committee. Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bbrc.2026.154712_bib33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2026.154712_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1070961","article-title":"PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154712_bib35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41467-025-56537-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced hepatocellular carcinoma: a phase II trial","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"issue":"28","key":"10.1016\/j.bbrc.2026.154712_bib36","first-page":"19671","article-title":"Antiapoptotic BCL-2 proteins determine sorafenib\/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma","volume":"9","author":"Tutusaus","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bbrc.2026.154712_bib37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.21037\/tcr.2019.07.11","article-title":"The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound","volume":"8","author":"Hou","year":"2019","journal-title":"Transl. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154712_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/cancers15020517","article-title":"AtomNet-aided OTUD7B inhibitor discovery and validation","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.bbrc.2026.154712_bib39","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.15252\/embr.201438850","article-title":"Cezanne (OTUD7B) regulates HIF-1\u03b1 homeostasis in a proteasome-independent manner","volume":"15","author":"Bremm","year":"2014","journal-title":"EMBO Rep."},{"issue":"7","key":"10.1016\/j.bbrc.2026.154712_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41389-021-00338-7","article-title":"USP29-mediated HIF1\u03b1 stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis","volume":"10","author":"Gao","year":"2021","journal-title":"Oncogenesis"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26014786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26014786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:03:29Z","timestamp":1793783009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26014786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":40,"alternative-id":["S0006291X26014786"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154712","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OTUD7B associates with immune infiltration and pharmacogenomic profiles in hepatocellular carcinoma: An integrative multi-omics analysis","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154712"}}